Prediction of high risk for death in patients with follicular lymphoma receiving rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisolone in first-line chemotherapy.-论文-万方医学网

作者： Satsuki,Murakami ^[1] ; Harumi,Kato ^[1] ; Yusuke,Higuchi ^[1] ; Kazuhito,Yamamoto ^[1] ; Hideyuki,Yamamoto ^[1] ; Toko,Saito ^[1] ; Hirofumi,Taji ^[1] ; Yasushi,Yatabe ^[2] ; Shigeo,Nakamura ^[2] ; Tomohiro,Kinoshita ^[3]

作者单位： Department of Hematology and Cell Therapy, Aichi Cancer Center Hospital, 1-1 Kanokoden, Chikusa-ku, Nagoya, Aichi, 464-8681, Japan. ^[1] Department of Pathology and Molecular Diagnostics, Aichi Cancer Center Hospital, Nagoya, Aichi, Japan. ^[2] Department of Pathology and Clinical Laboratory, Nagoya University Hospital, Nagoya, Aichi, Japan. ^[3] Department of Hematology and Cell Therapy, Aichi Cancer Center Hospital, 1-1 Kanokoden, Chikusa-ku, Nagoya, Aichi, 464-8681, Japan. kinosita@aichi-cc.jp. ^[4]

主题词成年人(Adult);老年人(Aged);抗肿瘤联合化疗方案(Antineoplastic Combined Chemotherapy Protocols);环磷酰胺(Cyclophosphamide);疾病恶化(Disease Progression);多柔比星(Doxorubicin);女(雌)性(Female);人类(Humans);Kaplan-Meiers评估(Kaplan-Meier Estimate);淋巴瘤, 滤泡性(Lymphoma, Follicular);男(雄)性(Male);中年人(Middle Aged);多元分析(Multivariate Analysis);泼尼松龙(Prednisolone);预后(Prognosis);比例危险度模型(Proportional Hazards Models);危险因素(Risk Factors);存活率(Survival Rate);时间因素(Time Factors);长春新碱(Vincristine)

DOI 10.1007/s00277-016-2690-2

PMID 27220639

发布时间 2019-12-10

检索历史清除

Prediction of high risk for death in patients with follicular lymphoma receiving rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisolone in first-line chemotherapy.

Annals of hematology

相似文献

Annals of hematology

相关期刊

参考文献：
指定格式：	NoteExpress EndNote RefWorks NoteFirst

检索历史 清除

Prediction of high risk for death in patients with follicular lymphoma receiving rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisolone in first-line chemotherapy.

Annals of hematology

相似文献

Annals of hematology

相关期刊

检索历史清除